Robert Marc Bober, MD
Cardiovascular Disease (Cardiology) · Oakland
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 10
- 2 carriers
- Offices
- 13
Offices
13 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Looking this up.
Hospitals listed: Alta Bates Summit Medical Center · Alta Bates Summit Medical Center - Alta Bates Camp · Eden Medical Center. That is not proof they admit you there this week.
Plans that list them
10 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Bober’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
10 of 10 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence C194195 · Current
Licensed to practise in California · since 2024 · expires 2028-04-30 · University of Maryland School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Alta Bates Summit Medical CenterOakland, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Death rate among surgical inpatients with serious treatable complications: 130.09 (87.72 to 172.46) · 109 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.274, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.227, Oct 2024 – Sep 2025
- Alta Bates Summit Medical Center - Alta Bates CampBerkeley, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.298, Oct 2024 – Sep 2025
- Eden Medical CenterCastro Valley, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 75% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.122, Oct 2024 – Sep 2025
See every measure and the patient survey for Alta Bates Summit Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 4 better, 3 the same, 0 worse of 7 measures. Readmissions: 3 better, 6 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 130.09 (87.72 to 172.46) · 109 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.274 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.227 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1 (0.06 to 1.94) · 1,209 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.88 (0.6 to 1.16) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.9 · 105 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.8 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 447 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.7 · 341 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.2 · 381 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 2,811 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.31) · 7,167 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,659 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.93 (0.92 to 4.94) · 1,668 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.25 (0 to 2.75) · 580 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.67 (1.19 to 4.15) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.17 (0.33 to 12.02) · 633 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 8.11 (4.67 to 11.55) · 619 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.07) · 309 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.39 (0 to 0.96) · 6,085 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.8 · 217 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.724 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.425 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.716 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 12.7 · 416 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.6 · 606 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -30.4 · 359 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -31.8 · 555 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -14.4 · 358 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16 · 382 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.1 (3.2 to 8.2) · 25 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.8 (7.3 to 16) · 25 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.5 · 232 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.9 · 56 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 152 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14.8 (11.1 to 20) · 251 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 579 cases | No different | Jan 2024 – Dec 2024 |
What patients said (535 patients answered, 18% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 73% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Alta Bates Summit Medical Center - Alta Bates Camp
Behind the star rating — Deaths: 2 better, 5 the same, 0 worse of 7 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 6 the same, 1 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.298 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.18 (0.16 to 2.2) · 730 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.87 (0.51 to 1.23) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 188.12 (132.31 to 243.94) · 50 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 6.8 · 50 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.4 · 189 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.6 · 184 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 103 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 1,585 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.4) · 3,929 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.31 (0.11 to 0.51) · 3,954 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.15 (0.95 to 5.36) · 754 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.62 (0 to 3.33) · 325 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.99 (0.39 to 3.59) · 717 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.85 (2.27 to 19.44) · 326 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.79 (1.08 to 8.49) · 302 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.68 (0.19 to 3.18) · 184 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.17 (0 to 0.88) · 3,240 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.4 · 161 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.207 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.48 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.785 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.4 · 243 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -58.2 · 194 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -12.3 · 177 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 209 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.4 (3.8 to 7.5) · 215 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.2 (9.4 to 15.5) · 215 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.8 · 150 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.2 · 81 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.4 (10 to 18.1) · 315 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1.2) · 137 cases | No different | Jan 2024 – Dec 2024 |
What patients said (449 patients answered, 15% of those asked)
| Cleanliness | 2 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 2 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 62% |
| Nurses "always" communicated well | 72% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 53% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 68% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 58% |
| Staff "always" explained new medications | 67% |
| Nurses "always" explained things so they could understand | 67% |
| Nurses "always" listened carefully | 66% |
| Nurses "always" treated them with courtesy and respect | 81% |
| "Always" quiet at night | 49% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 38% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
See every measure and the patient survey for Eden Medical Center
Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 7 the same, 0 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.122 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.88 (0 to 1.89) · 819 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.46 to 1.16) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 137.41 (92.94 to 181.88) · 70 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.4 · 78 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.7 · 38 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.1 · 207 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 17.6 · 359 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.5 · 355 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.4 · 1,714 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.17 (0 to 0.39) · 4,697 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.3 (0.1 to 0.5) · 4,676 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.69 (0.53 to 4.85) · 860 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.56 (0 to 3.24) · 251 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.75 (1.17 to 4.32) · 818 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.76 (0 to 15.78) · 261 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.09 (2.08 to 10.1) · 242 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.64 (0.16 to 3.12) · 233 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.85) · 4,132 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.9 · 60 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.431 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.292 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.307 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.61 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 258 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 22.6 · 225 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 2.4 · 367 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.9 · 390 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 58 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 88 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.9 (9.6 to 17.4) · 68 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1.1) · 205 cases | No different | Jan 2024 – Dec 2024 |
What patients said (431 patients answered, 17% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 58% |
| "YES", patients would definitely recommend the hospital | 75% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
Original Medicare doctor bills
$35,016
Medicare paid this office $35,016 for 364 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 27 | $5,489 | $203 |
| New patient visit (45+ min) | 33 | $5,015 | $152 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress with concurrent ct scan | 50 | $3,076 | $62 |
| Return visit (30+ min) | 21 | $2,545 | $116 |
| Return visit (30+ min) | 38 | $2,125 | $54 |
See all 14 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 27 | $5,489 | $203 |
| New patient visit (45+ min) | 33 | $5,015 | $152 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress with concurrent ct scan | 50 | $3,076 | $62 |
| Return visit (30+ min) | 21 | $2,545 | $116 |
| Return visit (30+ min) | 38 | $2,125 | $54 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 30 | $1,662 | $55 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 22 | $1,340 | $61 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 12 | $1,295 | $108 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 81 | $1,224 | $15 |
| Nuclear medicine study of heart muscle blood flow by pet | 48 | $980 | $20 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 81 | $811 | $10 |
| Heart muscle strain imaging | 15 | $578 | $39 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 28 | $359 | $13 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 81 | $318 | $4 |
Who their Medicare patients are
364 Original Medicare patients in 2024. Average age 74 · Under 65 10% · 85 and older 11% · Women 51% · Also on Medicaid 19% · Health risk score 1.97. Above the middle of the specialty; the typical cardiology clinician is at 1.71.
Conditions among them: High blood pressure 75% · Coronary heart disease 48% · Diabetes 40% · Chronic kidney disease 40% · Atrial fibrillation 38% · Heart failure 37% · COPD 21% · Cancer 20% · Depression 17% · Stroke 11% · Dementia 10%.
The office billed $150,698, Medicare allowed $46,802 and paid $35,016; for 727 services of 36 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 364 | 727 | 74 | 1.97 | $150,698 | $35,016 |
| 2023 | 486 | 1,062 | 73 | 2.17 | $115,639 | $29,990 |
| 2022 | 505 | 1,063 | 73 | 2.40 | $103,714 | $30,540 |
| 2021 | 516 | 1,024 | 70 | 2.35 | $109,066 | $31,213 |
| 2020 | 625 | 1,191 | 70 | 2.96 | $113,590 | $30,038 |
| 2019 | 1,156 | 1,946 | 69 | 2.97 | $132,184 | $34,950 |
| 2018 | 1,056 | 1,822 | 69 | 2.57 | $140,543 | $35,286 |
| 2017 | 511 | 1,086 | 70 | 2.33 | $138,666 | $39,955 |
| 2016 | 454 | 1,070 | 69 | 2.51 | $144,894 | $43,410 |
| 2015 | 425 | 1,004 | 71 | 2.33 | $141,432 | $43,937 |
| 2014 | 451 | 1,053 | 71 | 1.93 | $120,861 | $42,825 |
| 2013 | 526 | 1,264 | 70 | 2.19 | $132,532 | $46,847 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 10 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress with concurrent ct scan | 94 | $6,225 | $66 |
| Return visit (30+ min) | 54 | $3,877 | $72 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 56 | $3,026 | $54 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 17 | $2,546 | $62 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 151 | $2,399 | $16 |
| Nuclear medicine study of heart muscle blood flow by pet | 90 | $1,998 | $22 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 236 | $1,764 | $6 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 150 | $1,601 | $11 |
| New patient visit (45+ min) | 15 | $1,571 | $105 |
| Nuclear medicine study, spect imaging, 1 area or single acquisition, single day imaging | 12 | $390 | $33 |
2022: 9 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress with concurrent ct scan | 93 | $6,222 | $67 |
| Return visit (30+ min) | 75 | $5,513 | $66 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 18 | $2,886 | $152 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 49 | $2,804 | $57 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 139 | $2,333 | $17 |
| Nuclear medicine study of heart muscle blood flow by pet | 88 | $1,991 | $23 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 246 | $1,857 | $6 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 139 | $1,557 | $11 |
| New patient visit (45+ min) | 16 | $1,467 | $92 |
2021: 13 services
| Return visit (30+ min) | 78 | $6,610 | $77 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 24 | $3,866 | $161 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 54 | $3,099 | $57 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 267 | $2,258 | $6 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 33 | $2,063 | $63 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress with concurrent ct scan | 28 | $2,008 | $72 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 113 | $1,895 | $17 |
| New patient visit (45+ min) | 17 | $1,563 | $92 |
| Nuclear medicine study of heart muscle blood flow by pet | 59 | $1,357 | $23 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 113 | $1,258 | $11 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 11 | $1,156 | $58 |
| Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | 12 | $535 | $24 |
| Nuclear medicine study, spect imaging, 1 area or single acquisition, single day imaging | 11 | $450 | $41 |
2020: 10 services
| Return visit (30+ min) | 80 | $5,354 | $59 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 68 | $4,551 | $67 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 23 | $3,700 | $161 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 389 | $2,982 | $5 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 33 | $2,120 | $64 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 101 | $1,789 | $18 |
| Nuclear medicine study of heart muscle blood flow by pet | 60 | $1,506 | $25 |
| New patient visit (45+ min) | 17 | $1,501 | $88 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 101 | $1,190 | $12 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 13 | $1,158 | $58 |
2019: 8 services
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 902 | $8,883 | $6 |
| Return visit (30+ min) | 110 | $7,218 | $57 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 94 | $6,673 | $70 |
| New patient visit (45+ min) | 21 | $1,990 | $95 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 110 | $1,971 | $18 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 32 | $1,926 | $60 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 110 | $1,310 | $12 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 11 | $1,240 | $59 |
2018: 9 services
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 763 | $7,639 | $7 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 108 | $7,449 | $68 |
| Return visit (30+ min) | 110 | $6,392 | $54 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 45 | $2,731 | $61 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 148 | $2,525 | $17 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 13 | $1,990 | $153 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 148 | $1,707 | $11 |
| New patient visit (45+ min) | 12 | $1,208 | $101 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 15 | $176 | $7 |
2017: 10 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 185 | $12,595 | $67 |
| Return visit (30+ min) | 120 | $6,933 | $54 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 245 | $4,199 | $17 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 51 | $3,160 | $62 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 245 | $2,792 | $11 |
| New patient visit (45+ min) | 26 | $2,291 | $88 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 14 | $2,279 | $163 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 14 | $1,446 | $58 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 80 | $612 | $7 |
| Short return visit (20+ min) | 11 | $450 | $41 |
2016: 11 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 152 | $10,829 | $69 |
| Return visit (30+ min) | 106 | $6,593 | $54 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 94 | $5,825 | $62 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 258 | $4,582 | $17 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 20 | $3,254 | $163 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 258 | $2,973 | $11 |
| Hospital discharge day management, more than 30 minutes | 33 | $2,740 | $83 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 24 | $1,962 | $54 |
| New patient visit (45+ min) | 14 | $1,258 | $90 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 15 | $570 | $29 |
| Short return visit (20+ min) | 14 | $533 | $38 |
2015: 13 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 152 | $10,905 | $72 |
| Return visit (30+ min) | 110 | $6,677 | $54 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 35 | $3,982 | $57 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 216 | $3,791 | $17 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 22 | $3,765 | $164 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 54 | $3,294 | $61 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 216 | $2,459 | $11 |
| Hospital discharge day management, more than 30 minutes | 29 | $2,409 | $83 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 11 | $1,953 | $81 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 14 | $1,152 | $82 |
| New patient visit (45+ min) | 11 | $867 | $79 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 18 | $595 | $31 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 23 | $164 | $7 |
2014: 13 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 158 | $11,294 | $71 |
| Return visit (30+ min) | 112 | $7,264 | $55 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 66 | $3,927 | $59 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 224 | $3,860 | $17 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 19 | $2,977 | $157 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 226 | $2,581 | $11 |
| New patient visit (45+ min) | 24 | $2,321 | $97 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 12 | $2,067 | $80 |
| Hospital discharge day management, more than 30 minutes | 21 | $1,760 | $80 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 14 | $1,476 | $55 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 14 | $681 | $31 |
| Short return visit (20+ min) | 14 | $527 | $38 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 51 | $391 | $6 |
2013: 10 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 225 | $15,041 | $67 |
| Return visit (30+ min) | 131 | $8,781 | $55 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 90 | $5,119 | $57 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 301 | $5,018 | $17 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 308 | $3,421 | $11 |
| New patient visit (45+ min) | 22 | $2,028 | $92 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 11 | $1,649 | $150 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 13 | $1,139 | $54 |
| Short return visit (20+ min) | 11 | $387 | $35 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 37 | $272 | $6 |
Medicaid work
$430 in 2024
Medicaid paid $430 for 83 billed services this clinician did in 2024, up to 57 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 83 | $430 |
| 2024 | 83 | 1 | 57 | $430 |
| 2023 | 420 | 3 | 164 | $1,738 |
| 2022 | 431 | 3 | 157 | $2,163 |
| 2021 | 523 | 3 | 169 | $2,222 |
| 2020 | 585 | 1 | 200 | $2,594 |
| 2019 | 1,455 | 1 | 207 | $5,521 |
| 2018 | 1,146 | 1 | 173 | $4,264 |
See the largest Medicaid services in earlier years
2023
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 392 | $1,604 |
| CARDIOVASCULAR STRESS TEST | 14 | $81 |
| CARDIOVASCULAR STRESS TEST | 14 | $53 |
2022
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 375 | $1,739 |
| CARDIOVASCULAR STRESS TEST | 28 | $255 |
| CARDIOVASCULAR STRESS TEST | 28 | $169 |
2021
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 493 | $1,989 |
| CARDIOVASCULAR STRESS TEST | 15 | $140 |
| CARDIOVASCULAR STRESS TEST | 15 | $93 |
2020
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 585 | $2,594 |
2019
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 1,455 | $5,521 |
2018
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 1,146 | $4,264 |
Drugs they prescribed that Part D paid
$280,626
Pharmacies billed $280,626 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,615) in 2024. At or below the middle of the specialty; the typical cardiology clinician is at 0%.
1,271 generic and fewer than 11 brand-name prescriptions · $280,626 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Eliquis | 91 | $80,876 | $889 |
| Entresto | 41 | $32,407 | $790 |
| Repatha Sureclick | 57 | $31,712 | $556 |
| Ozempic | 13 | $23,644 | $1,819 |
| Jardiance | 25 | $21,994 | $880 |
See all 32 drugs
| Eliquis | 91 | $80,876 | $889 |
| Entresto | 41 | $32,407 | $790 |
| Repatha Sureclick | 57 | $31,712 | $556 |
| Ozempic | 13 | $23,644 | $1,819 |
| Jardiance | 25 | $21,994 | $880 |
| Praluent | 31 | $17,074 | $551 |
| Brilinta | 22 | $11,199 | $509 |
| Vascepa | 11 | $3,806 | $346 |
| Rosuvastatin | 185 | $2,373 | $13 |
| Atorvastatin | 121 | $1,922 | $16 |
| Metoprolol | 89 | $1,391 | $16 |
| Valsartan | 48 | $973 | $20 |
| Clopidogrel | 64 | $872 | $14 |
| Nifedipine Er | 29 | $654 | $23 |
| Ezetimibe | 51 | $645 | $13 |
| Isosorbide Mononitrate Er | 47 | $575 | $12 |
| Carvedilol | 71 | $542 | $8 |
| Telmisartan | 15 | $482 | $32 |
| Amlodipine Besylate | 94 | $461 | $5 |
| Olmesartan Medoxomil | 27 | $460 | $17 |
| Nitroglycerin | 19 | $345 | $18 |
| Warfarin | 21 | $345 | $16 |
| Losartan | 47 | $332 | $7 |
| Hydralazine | 15 | $282 | $19 |
| Irbesartan | 13 | $255 | $20 |
| Spironolactone | 21 | $223 | $11 |
| Metoprolol | 18 | $207 | $11 |
| Chlorthalidone | 17 | $187 | $11 |
| Lisinopril | 17 | $142 | $8 |
| Furosemide | 29 | $135 | $5 |
| Hydrochlorothiazide | 43 | $126 | $3 |
| Losartan-Hydrochlorothiazide | 15 | $88 | $6 |
Year by year
| 2024 | 1,615 | 312 | 0% (0) | None | $280,626 |
| 2023 | 1,959 | 343 | 0% (0) | 20% | $386,283 |
| 2022 | 2,177 | 361 | 0% (0) | 17% | $336,857 |
| 2021 | 2,398 | 366 | 0% (0) | 15% | $272,012 |
| 2020 | 2,310 | 350 | 0% (0) | None | $220,382 |
| 2019 | 2,397 | 334 | 0% (0) | 14% | $194,545 |
| 2018 | 2,459 | 311 | 0% (0) | 12% | $160,670 |
| 2017 | 2,815 | 304 | None | 13% | $158,805 |
| 2016 | 2,607 | 288 | 0% (0) | 16% | $175,919 |
| 2015 | 2,775 | 275 | 0% (0) | 20% | $177,508 |
| 2014 | 3,131 | 310 | 0% (0) | 24% | $182,250 |
| 2013 | 3,594 | 309 | 0% (0) | 26% | $188,951 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 35 drugs
| Eliquis | 94 | $102,435 | $1,090 |
| Entresto | 90 | $88,349 | $982 |
| Repatha Sureclick | 60 | $35,196 | $587 |
| Trulicity | 12 | $24,051 | $2,004 |
| Praluent | 40 | $23,931 | $598 |
| Jardiance | 18 | $20,462 | $1,137 |
| Ozempic | 12 | $11,401 | $950 |
| Brilinta | 13 | $9,043 | $696 |
| Rosuvastatin | 200 | $2,973 | $15 |
| Atorvastatin | 162 | $2,490 | $15 |
| Metoprolol | 96 | $2,250 | $23 |
| Valsartan | 67 | $1,600 | $24 |
| Clopidogrel | 85 | $1,400 | $16 |
| Irbesartan | 30 | $1,117 | $37 |
| Isosorbide Mononitrate Er | 46 | $1,054 | $23 |
| Ezetimibe | 54 | $1,009 | $19 |
| Midodrine | 12 | $992 | $83 |
| Carvedilol | 84 | $718 | $9 |
| Nifedipine Er | 22 | $682 | $31 |
| Losartan | 72 | $674 | $9 |
| Nitroglycerin | 29 | $657 | $23 |
| Amlodipine Besylate | 109 | $555 | $5 |
| Olmesartan Medoxomil | 39 | $542 | $14 |
| Telmisartan | 21 | $466 | $22 |
| Labetalol | 16 | $459 | $29 |
| Hydralazine | 17 | $231 | $14 |
| Chlorthalidone | 17 | $190 | $11 |
| Benazepril | 13 | $188 | $14 |
| Spironolactone | 19 | $180 | $9 |
| Lisinopril | 28 | $177 | $6 |
| Metoprolol | 24 | $175 | $7 |
| Hydrochlorothiazide | 65 | $174 | $3 |
| Furosemide | 36 | $146 | $4 |
| Losartan-Hydrochlorothiazide | 20 | $100 | $5 |
| Atenolol | 13 | $35 | $3 |
2022: 38 drugs
| Eliquis | 143 | $138,714 | $970 |
| Entresto | 54 | $49,291 | $913 |
| Repatha Sureclick | 48 | $25,692 | $535 |
| Xarelto | 16 | $24,709 | $1,544 |
| Praluent | 24 | $12,781 | $533 |
| Brilinta | 14 | $8,991 | $642 |
| Rosuvastatin | 235 | $4,002 | $17 |
| Valsartan | 72 | $2,588 | $36 |
| Atorvastatin | 160 | $2,289 | $14 |
| Metoprolol | 89 | $2,171 | $24 |
| Flecainide Acetate | 14 | $2,122 | $152 |
| Candesartan Cilexetil | 13 | $2,006 | $154 |
| Ezetimibe | 72 | $1,737 | $24 |
| Carvedilol | 151 | $1,635 | $11 |
| Nifedipine Er | 26 | $1,393 | $54 |
| Isosorbide Mononitrate Er | 58 | $1,237 | $21 |
| Clopidogrel | 79 | $1,230 | $16 |
| Nitroglycerin | 35 | $1,104 | $32 |
| Amlodipine Besylate | 149 | $1,032 | $7 |
| Telmisartan | 28 | $850 | $30 |
| Irbesartan | 43 | $837 | $19 |
| Losartan | 83 | $817 | $10 |
| Labetalol | 13 | $679 | $52 |
| Valsartan-Hydrochlorothiazide | 15 | $556 | $37 |
| Olmesartan Medoxomil | 36 | $533 | $15 |
| Spironolactone | 34 | $415 | $12 |
| Metoprolol | 43 | $396 | $9 |
| Furosemide | 51 | $348 | $7 |
| Chlorthalidone | 23 | $281 | $12 |
| Amiodarone | 12 | $275 | $23 |
| Hydrochlorothiazide | 62 | $240 | $4 |
| Omeprazole | 16 | $228 | $14 |
| Lisinopril | 44 | $225 | $5 |
| Hydralazine | 16 | $216 | $13 |
| Losartan-Hydrochlorothiazide | 14 | $110 | $8 |
| Warfarin | 13 | $105 | $8 |
| Benazepril | 18 | $96 | $5 |
| Atenolol | 14 | $35 | $3 |
2021: 41 drugs
| Eliquis | 144 | $123,033 | $854 |
| Xarelto | 23 | $22,249 | $967 |
| Entresto | 23 | $20,253 | $881 |
| Praluent | 39 | $18,661 | $478 |
| Repatha Sureclick | 33 | $16,551 | $502 |
| Pradaxa | 16 | $8,007 | $500 |
| Rosuvastatin | 267 | $3,221 | $12 |
| Valsartan | 89 | $2,590 | $29 |
| Metoprolol | 111 | $2,479 | $22 |
| Ezetimibe | 71 | $2,341 | $33 |
| Isosorbide Mononitrate Er | 87 | $2,026 | $23 |
| Atorvastatin | 166 | $1,879 | $11 |
| Omega-3 Acid Ethyl Esters | 11 | $1,730 | $157 |
| Candesartan Cilexetil | 14 | $1,653 | $118 |
| Prasugrel | 11 | $1,396 | $127 |
| Carvedilol | 153 | $1,342 | $9 |
| Irbesartan | 58 | $1,041 | $18 |
| Losartan | 105 | $940 | $9 |
| Nifedipine Er | 27 | $923 | $34 |
| Amlodipine Besylate | 170 | $899 | $5 |
| Nitroglycerin | 39 | $862 | $22 |
| Valsartan-Hydrochlorothiazide | 20 | $845 | $42 |
| Clopidogrel | 82 | $803 | $10 |
| Labetalol | 13 | $646 | $50 |
| Olmesartan Medoxomil | 47 | $556 | $12 |
| Flecainide Acetate | 11 | $550 | $50 |
| Metoprolol | 51 | $420 | $8 |
| Furosemide | 67 | $407 | $6 |
| Chlorthalidone | 23 | $391 | $17 |
| Hydralazine | 19 | $348 | $18 |
| Pravastatin | 22 | $298 | $14 |
| Hydrochlorothiazide | 50 | $291 | $6 |
| Spironolactone | 37 | $286 | $8 |
| Warfarin | 30 | $259 | $9 |
| Amiodarone | 12 | $259 | $22 |
| Lisinopril | 48 | $253 | $5 |
| Omeprazole | 11 | $215 | $20 |
| Losartan-Hydrochlorothiazide | 14 | $170 | $12 |
| Benazepril | 20 | $91 | $5 |
| Clonidine | 12 | $78 | $7 |
| Atenolol | 19 | $62 | $3 |
2020: 37 drugs
| Eliquis | 80 | $62,421 | $780 |
| Xarelto | 42 | $35,089 | $835 |
| Entresto | 31 | $26,937 | $869 |
| Repatha Sureclick | 23 | $10,868 | $473 |
| Praluent | 14 | $7,328 | $523 |
| Pradaxa | 14 | $6,698 | $478 |
| Brilinta | 12 | $6,507 | $542 |
| Rosuvastatin | 286 | $4,204 | $15 |
| Ezetimibe | 74 | $3,468 | $47 |
| Metoprolol | 127 | $3,220 | $25 |
| Isosorbide Mononitrate Er | 88 | $2,954 | $34 |
| Atorvastatin | 186 | $2,857 | $15 |
| Valsartan | 60 | $2,311 | $39 |
| Irbesartan | 57 | $1,748 | $31 |
| Candesartan Cilexetil | 13 | $1,610 | $124 |
| Clopidogrel | 80 | $1,542 | $19 |
| Carvedilol | 126 | $1,465 | $12 |
| Olmesartan Medoxomil | 45 | $997 | $22 |
| Amlodipine Besylate | 139 | $964 | $7 |
| Losartan | 93 | $918 | $10 |
| Nitroglycerin | 36 | $905 | $25 |
| Chlorthalidone | 23 | $853 | $37 |
| Valsartan-Hydrochlorothiazide | 21 | $753 | $36 |
| Nifedipine Er | 19 | $704 | $37 |
| Warfarin | 44 | $682 | $16 |
| Metoprolol | 62 | $607 | $10 |
| Furosemide | 82 | $598 | $7 |
| Labetalol | 13 | $568 | $44 |
| Diltiazem 24hr Er (Cd) | 14 | $536 | $38 |
| Pravastatin | 20 | $516 | $26 |
| Hydralazine | 18 | $460 | $26 |
| Lisinopril | 62 | $447 | $7 |
| Spironolactone | 34 | $416 | $12 |
| Hydrochlorothiazide | 67 | $385 | $6 |
| Losartan-Hydrochlorothiazide | 13 | $287 | $22 |
| Atenolol | 24 | $130 | $5 |
| Benazepril | 18 | $85 | $5 |
2019: 35 drugs
| Eliquis | 83 | $55,991 | $675 |
| Xarelto | 38 | $26,267 | $691 |
| Pradaxa | 26 | $14,052 | $540 |
| Praluent | 13 | $13,881 | $1,068 |
| Entresto | 14 | $7,350 | $525 |
| Brilinta | 18 | $6,837 | $380 |
| Rosuvastatin | 238 | $5,696 | $24 |
| Atorvastatin | 210 | $5,049 | $24 |
| Metoprolol | 134 | $4,415 | $33 |
| Valsartan | 78 | $3,834 | $49 |
| Isosorbide Mononitrate Er | 92 | $2,919 | $32 |
| Irbesartan | 48 | $2,583 | $54 |
| Ezetimibe | 41 | $2,000 | $49 |
| Pravastatin | 48 | $1,802 | $38 |
| Carvedilol | 143 | $1,559 | $11 |
| Flecainide Acetate | 18 | $1,523 | $85 |
| Chlorthalidone | 30 | $1,491 | $50 |
| Amlodipine Besylate | 138 | $1,299 | $9 |
| Losartan | 98 | $1,280 | $13 |
| Nitroglycerin | 41 | $1,025 | $25 |
| Nifedipine Er | 17 | $964 | $57 |
| Clopidogrel | 86 | $953 | $11 |
| Warfarin | 62 | $891 | $14 |
| Metoprolol | 91 | $861 | $9 |
| Labetalol | 13 | $858 | $66 |
| Lisinopril | 96 | $719 | $7 |
| Olmesartan Medoxomil | 24 | $631 | $26 |
| Furosemide | 93 | $610 | $7 |
| Hydrochlorothiazide | 63 | $411 | $7 |
| Hydralazine | 14 | $411 | $29 |
| Spironolactone | 23 | $408 | $18 |
| Losartan-Hydrochlorothiazide | 17 | $288 | $17 |
| Valsartan-Hydrochlorothiazide | 12 | $137 | $11 |
| Atenolol | 23 | $124 | $5 |
| Benazepril | 14 | $92 | $7 |
2018: 39 drugs
| Eliquis | 59 | $33,501 | $568 |
| Xarelto | 42 | $19,558 | $466 |
| Pradaxa | 33 | $18,833 | $571 |
| Praluent | 14 | $15,131 | $1,081 |
| Atorvastatin | 241 | $5,085 | $21 |
| Metoprolol | 141 | $5,024 | $36 |
| Rosuvastatin | 156 | $3,598 | $23 |
| Diovan | 11 | $3,298 | $300 |
| Pravastatin | 87 | $2,199 | $25 |
| Isosorbide Mononitrate Er | 80 | $2,189 | $27 |
| Carvedilol | 180 | $1,873 | $10 |
| Ezetimibe | 16 | $1,860 | $116 |
| Prasugrel | 15 | $1,772 | $118 |
| Valsartan | 41 | $1,541 | $38 |
| Losartan | 104 | $1,508 | $14 |
| Amlodipine Besylate | 130 | $1,412 | $11 |
| Nifedipine Er | 24 | $1,273 | $53 |
| Nitroglycerin | 42 | $1,237 | $29 |
| Chlorthalidone | 33 | $1,199 | $36 |
| Lisinopril | 136 | $1,196 | $9 |
| Irbesartan | 48 | $1,154 | $24 |
| Flecainide Acetate | 26 | $1,153 | $44 |
| Warfarin | 72 | $1,093 | $15 |
| Clopidogrel | 84 | $926 | $11 |
| Metoprolol | 82 | $806 | $10 |
| Furosemide | 109 | $699 | $6 |
| Isosorbide Dinitrate | 15 | $665 | $44 |
| Hydrochlorothiazide | 95 | $645 | $7 |
| Dilt-Xr | 12 | $533 | $44 |
| Hydralazine | 22 | $529 | $24 |
| Potassium Chloride | 21 | $437 | $21 |
| Torsemide | 13 | $310 | $24 |
| Spironolactone | 21 | $272 | $13 |
| Losartan-Hydrochlorothiazide | 14 | $235 | $17 |
| Simvastatin | 19 | $188 | $10 |
| Benazepril | 16 | $161 | $10 |
| Sotalol | 12 | $157 | $13 |
| Atenolol | 23 | $145 | $6 |
| Lisinopril-Hydrochlorothiazide | 13 | $125 | $10 |
2017: 44 drugs
| Xarelto | 45 | $21,629 | $481 |
| Eliquis | 35 | $16,680 | $477 |
| Pradaxa | 31 | $16,387 | $529 |
| Praluent | 12 | $13,006 | $1,084 |
| Effient | 16 | $8,821 | $551 |
| Metoprolol | 188 | $7,376 | $39 |
| Atorvastatin | 303 | $5,416 | $18 |
| Rosuvastatin | 153 | $4,300 | $28 |
| Omega-3 Acid Ethyl Esters | 15 | $3,391 | $226 |
| Diovan | 11 | $3,038 | $276 |
| Pravastatin | 100 | $2,506 | $25 |
| Isosorbide Mononitrate Er | 70 | $1,648 | $24 |
| Carvedilol | 175 | $1,627 | $9 |
| Warfarin | 113 | $1,495 | $13 |
| Losartan | 95 | $1,417 | $15 |
| Chlorthalidone | 35 | $1,387 | $40 |
| Amlodipine Besylate | 159 | $1,348 | $8 |
| Ezetimibe | 11 | $1,326 | $121 |
| Clopidogrel | 88 | $1,263 | $14 |
| Isosorbide Dinitrate | 15 | $1,254 | $84 |
| Valsartan | 55 | $1,216 | $22 |
| Lisinopril | 146 | $1,102 | $8 |
| Nitroglycerin | 33 | $1,100 | $33 |
| Hydrochlorothiazide | 123 | $1,049 | $9 |
| Metoprolol | 118 | $1,010 | $9 |
| Furosemide | 158 | $836 | $5 |
| Flecainide Acetate | 22 | $782 | $36 |
| Nifedipine Er | 22 | $669 | $30 |
| Potassium Chloride | 26 | $592 | $23 |
| Hydralazine | 29 | $580 | $20 |
| Digoxin | 16 | $559 | $35 |
| Levothyroxine | 18 | $345 | $19 |
| Atenolol | 37 | $292 | $8 |
| Pantoprazole | 24 | $268 | $11 |
| Benazepril | 23 | $267 | $12 |
| Losartan-Hydrochlorothiazide | 14 | $256 | $18 |
| Simvastatin | 23 | $229 | $10 |
| Irbesartan | 16 | $224 | $14 |
| Ramipril | 13 | $185 | $14 |
| Sotalol | 12 | $174 | $15 |
| Spironolactone | 15 | $167 | $11 |
| Amiodarone | 17 | $166 | $10 |
| Lisinopril-Hydrochlorothiazide | 21 | $160 | $8 |
| Clonidine | 14 | $124 | $9 |
2016: 39 drugs
| Xarelto | 51 | $26,570 | $521 |
| Crestor | 66 | $26,289 | $398 |
| Pradaxa | 42 | $23,195 | $552 |
| Zetia | 28 | $20,916 | $747 |
| Metoprolol | 174 | $8,511 | $49 |
| Atorvastatin | 303 | $6,673 | $22 |
| Effient | 17 | $6,576 | $387 |
| Omega-3 Acid Ethyl Esters | 11 | $3,561 | $324 |
| Pravastatin | 95 | $3,053 | $32 |
| Diovan | 11 | $2,677 | $243 |
| Warfarin | 121 | $1,664 | $14 |
| Carvedilol | 170 | $1,560 | $9 |
| Lisinopril | 187 | $1,352 | $7 |
| Valsartan | 32 | $1,229 | $38 |
| Flecainide Acetate | 25 | $1,187 | $47 |
| Rosuvastatin | 25 | $1,183 | $47 |
| Amlodipine Besylate | 164 | $1,174 | $7 |
| Isosorbide Mononitrate Er | 52 | $1,141 | $22 |
| Hydrochlorothiazide | 136 | $1,074 | $8 |
| Potassium Chloride | 39 | $1,073 | $28 |
| Chlorthalidone | 14 | $883 | $63 |
| Nitrostat | 25 | $795 | $32 |
| Clopidogrel | 69 | $777 | $11 |
| Metoprolol | 91 | $771 | $8 |
| Losartan | 76 | $759 | $10 |
| Furosemide | 138 | $732 | $5 |
| Digoxin | 16 | $680 | $42 |
| Levothyroxine | 19 | $341 | $18 |
| Benazepril | 18 | $327 | $18 |
| Hydralazine | 15 | $312 | $21 |
| Atenolol | 41 | $291 | $7 |
| Lisinopril-Hydrochlorothiazide | 30 | $221 | $7 |
| Simvastatin | 19 | $207 | $11 |
| Ramipril | 17 | $182 | $11 |
| Lovastatin | 15 | $174 | $12 |
| Clonidine | 19 | $166 | $9 |
| Spironolactone | 19 | $159 | $8 |
| Fosinopril | 15 | $108 | $7 |
| Gemfibrozil | 12 | $94 | $8 |
2015: 36 drugs
| Crestor | 128 | $44,899 | $351 |
| Pradaxa | 64 | $27,757 | $434 |
| Xarelto | 59 | $20,473 | $347 |
| Zetia | 23 | $12,491 | $543 |
| Effient | 27 | $8,589 | $318 |
| Omega-3 Acid Ethyl Esters | 18 | $8,093 | $450 |
| Metoprolol | 162 | $6,393 | $39 |
| Atorvastatin | 284 | $5,912 | $21 |
| Pravastatin | 99 | $3,476 | $35 |
| Valsartan | 28 | $2,017 | $72 |
| Warfarin | 117 | $1,864 | $16 |
| Benicar Hct | 12 | $1,682 | $140 |
| Losartan | 136 | $1,505 | $11 |
| Lisinopril | 206 | $1,423 | $7 |
| Carvedilol | 188 | $1,394 | $7 |
| Isosorbide Mononitrate Er | 76 | $1,335 | $18 |
| Metoprolol | 124 | $1,044 | $8 |
| Potassium Chloride | 34 | $949 | $28 |
| Amlodipine Besylate | 157 | $926 | $6 |
| Hydrochlorothiazide | 128 | $913 | $7 |
| Furosemide | 134 | $774 | $6 |
| Nitrostat | 27 | $747 | $28 |
| Clopidogrel | 58 | $706 | $12 |
| Flecainide Acetate | 19 | $647 | $34 |
| Levothyroxine | 19 | $353 | $19 |
| Lovastatin | 30 | $333 | $11 |
| Ramipril | 35 | $331 | $9 |
| Atenolol | 39 | $317 | $8 |
| Benazepril | 29 | $306 | $11 |
| Lisinopril-Hydrochlorothiazide | 34 | $294 | $9 |
| Simvastatin | 21 | $149 | $7 |
| Spironolactone | 23 | $148 | $6 |
| Amiodarone | 12 | $144 | $12 |
| Clonidine | 15 | $138 | $9 |
| Fosinopril | 16 | $122 | $8 |
| Gemfibrozil | 12 | $105 | $9 |
2014: 45 drugs
| Crestor | 174 | $47,792 | $275 |
| Pradaxa | 81 | $30,878 | $381 |
| Diovan | 39 | $11,003 | $282 |
| Zetia | 30 | $10,323 | $344 |
| Metoprolol | 217 | $8,525 | $39 |
| Atorvastatin | 269 | $6,502 | $24 |
| Effient | 24 | $6,314 | $263 |
| Lovaza | 20 | $6,216 | $311 |
| Xarelto | 21 | $6,119 | $291 |
| Pravastatin | 114 | $4,780 | $42 |
| Omega-3 Acid Ethyl Esters | 11 | $3,350 | $305 |
| Plavix | 12 | $2,399 | $200 |
| Vytorin | 12 | $2,257 | $188 |
| Benicar | 12 | $2,001 | $167 |
| Warfarin | 193 | $1,821 | $9 |
| Lisinopril | 221 | $1,589 | $7 |
| Toprol Xl | 13 | $1,454 | $112 |
| Carvedilol | 162 | $1,401 | $9 |
| Clopidogrel | 85 | $1,361 | $16 |
| Losartan | 136 | $1,354 | $10 |
| Isosorbide Mononitrate Er | 55 | $1,049 | $19 |
| Metoprolol | 139 | $1,027 | $7 |
| Hydrochlorothiazide | 130 | $931 | $7 |
| Amlodipine Besylate | 135 | $926 | $7 |
| Potassium Chloride | 31 | $908 | $29 |
| Furosemide | 145 | $722 | $5 |
| Flecainide Acetate | 17 | $701 | $41 |
| Nitrostat | 41 | $650 | $16 |
| Coumadin | 11 | $649 | $59 |
| Losartan-Hydrochlorothiazide | 35 | $609 | $17 |
| Lovastatin | 27 | $511 | $19 |
| Atenolol | 72 | $488 | $7 |
| Ramipril | 33 | $440 | $13 |
| Benazepril | 28 | $370 | $13 |
| Sotalol | 14 | $329 | $23 |
| Levothyroxine | 18 | $290 | $16 |
| Amiodarone | 15 | $278 | $19 |
| Lisinopril-Hydrochlorothiazide | 34 | $257 | $8 |
| Gemfibrozil | 21 | $255 | $12 |
| Simvastatin | 36 | $253 | $7 |
| Chlorthalidone | 13 | $230 | $18 |
| Clonidine | 24 | $195 | $8 |
| Omeprazole | 14 | $192 | $14 |
| Pantoprazole | 14 | $125 | $9 |
| Fosinopril | 14 | $94 | $7 |
2013: 46 drugs
| Crestor | 175 | $39,736 | $227 |
| Pradaxa | 76 | $22,436 | $295 |
| Lovaza | 40 | $14,152 | $354 |
| Metoprolol | 244 | $10,762 | $44 |
| Atorvastatin | 324 | $10,683 | $33 |
| Diovan | 44 | $10,621 | $241 |
| Zetia | 39 | $9,892 | $254 |
| Effient | 35 | $7,995 | $228 |
| Fenofibrate | 33 | $4,172 | $126 |
| Pravastatin | 134 | $3,446 | $26 |
| Clopidogrel | 96 | $3,441 | $36 |
| Losartan | 128 | $2,608 | $20 |
| Plavix | 12 | $2,428 | $202 |
| Diovan Hct | 12 | $2,308 | $192 |
| Carvedilol | 160 | $1,895 | $12 |
| Lisinopril | 264 | $1,813 | $7 |
| Benicar | 11 | $1,617 | $147 |
| Hydrochlorothiazide | 203 | $1,463 | $7 |
| Losartan-Hydrochlorothiazide | 24 | $1,405 | $59 |
| Warfarin | 151 | $1,325 | $9 |
| Metoprolol | 198 | $1,308 | $7 |
| Amlodipine Besylate | 135 | $1,251 | $9 |
| Furosemide | 219 | $1,084 | $5 |
| Toprol Xl | 17 | $1,080 | $64 |
| Coumadin | 17 | $835 | $49 |
| Isosorbide Mononitrate Er | 60 | $782 | $13 |
| Fenofibrate | 13 | $705 | $54 |
| Nitrostat | 48 | $697 | $15 |
| Potassium Chloride | 20 | $588 | $29 |
| Atenolol | 86 | $572 | $7 |
| Ramipril | 38 | $524 | $14 |
| Spironolactone | 26 | $523 | $20 |
| Flecainide Acetate | 18 | $504 | $28 |
| Lovastatin | 31 | $457 | $15 |
| Simvastatin | 38 | $454 | $12 |
| Omeprazole | 16 | $351 | $22 |
| Benazepril | 23 | $298 | $13 |
| Amiodarone | 15 | $294 | $20 |
| Gemfibrozil | 22 | $285 | $13 |
| Lisinopril-Hydrochlorothiazide | 23 | $222 | $10 |
| Pantoprazole | 22 | $221 | $10 |
| Clonidine | 21 | $211 | $10 |
| Quinapril | 16 | $198 | $12 |
| Levothyroxine | 23 | $195 | $8 |
| Klor-Con M20 | 11 | $145 | $13 |
| Fosinopril | 11 | $69 | $6 |
Money from drug and device companies
$540 in 2025
| 2025 | 3 | 7 | None | $540 |
| 2024 | 1 | 2 | None | $110 |
| 2023 | 1 | 18 | None | $386 |
| 2022 | 4 | 12 | None | $462 |
| 2021 | 4 | 5 | None | $264 |
| 2020 | 2 | 3 | $1,785 | $2,079 |
| 2019 | 1 | 7 | $8,171 | $8,582 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| AtriCure | Epi-Sense Guided Coagulation System With Visitrax | $420 | 4 payments
|
| Bracco Diagnostics | Cardiogen-82 | $95 | 2 payments
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $25 | 1 payment
|
See all 7 published payments
| AtriCure | Meals · 2025-09-13 | Epi-Sense Guided Coagulation System With Visitrax | $103 |
| AtriCure | Meals · 2025-09-13 | Epi-Sense Guided Coagulation System With Visitrax | $53 |
| AtriCure | Meals · 2025-09-13 | Epi-Sense Guided Coagulation System With Visitrax | $89 |
| AtriCure | Meals · 2025-09-12 | Epi-Sense Guided Coagulation System With Visitrax | $175 |
| Bracco Diagnostics | Meals · 2025-09-07 | Cardiogen-82 | $59 |
| Bracco Diagnostics | Meals · 2025-09-05 | Cardiogen-82 | $36 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-05-27 | Kerendia | $25 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $110
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $110 | 2 payments
|
2023: $386
| Bracco Diagnostics | Cardiogen-82 | $386 | 9 payments
|
2022: $462
| Bracco Diagnostics | Cardiogen-82 | $272 | 9 payments
|
| Abbott Laboratories | Gallant | $90 | 1 payment
|
| Medtronic | Micra | $85 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $15 | 1 payment
|
2021: $264
| Abiomed | Impella | $149 | 1 payment
|
| Bracco Diagnostics | Cardiogen-82 | $84 | 2 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $18 | 1 payment
|
| Esperion Therapeutics | Nexletol | $13 | 1 payment
|
2020: $2,079
| Ge Healthcare | None | $2,067 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $12 | 1 payment
|
2019: $8,582
| Bracco Diagnostics | Cardiogen | $8,582 | 7 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Bracco Diagnostics Inc. · Comparison of Mbf and Cfr Measurements As Calculated By Heartsee, Using Pet Mpi Data Obtained With Rb-82 Infused at 50 Vs. 20 Ml/Min Using the Cardiogen-82 Model 1700 Infusion System · 2022 | Their institution | $88,065 |
| Bracco Diagnostics Inc. · Bober the Impact of Absolute Resting Myocardial Flow and Coronary Flow Reserve on Left Ventricular Geometries, Renal Function and Death · 2020 | Their institution | $22,230 |
| BRACCO DIAGNOSTICS INC. · Impact of Gender, Body Mass Index and Breast Cup Size on the Correlation Between Single Photon Emission Computed Tomography and Coronary Angiography · 2019 | Their institution | $22,230 |
| GE HEALTHCARE · A Phase 3 Open Label Multicenter Study of Flurpiridaz (18f) Injection for Positive Emission Tomography (Pet) Imaging for Assessment of Myocardial Perfusion in Patients Referred for Invasive Coronary Angiography Because of Suspected Coronary Artery Disease · 2021 | Their institution | $18,245 |
| Bracco Diagnostics Inc. · Comparison of Mbf and Cfr Measurements As Calculated By Heartsee, Using Pet Mpi Data Obtained With Rb-82 Infused at 50 Vs. 20 Ml/Min Using the Cardiogen-82 Model 1700 Infusion System. · 2022 | Their institution | $17,613 |
| GE HEALTHCARE · A Phase 3| Open Label| Multicenter Study of Flurpiridaz (18f) Injection for Positive Emission Tomography (Pet) Imaging · 2020 | Their institution | $12,291 |
| Bracco Diagnostics Inc. · Iis-US-0147 · 2023 | Their institution | $11,742 |
| GE HEALTHCARE · A Phase 3 Open Label Multicentre Study of Flurpiridaz (18f) Injection for Positron Emission Tomography (Pet) Imaging for Assessment of Myocardial Perfusion in Patients Referred for Invasive Coronary Angiography Because of Suspected Coronary Artery Disease · 2019 | Their institution | $9,500 |
| GE HEALTHCARE · A Phase 3| Open Label| Multicenter Study of Flurpiridaz (18f) Injection for Positive Emission Tomography (Pet) Imaging for Assessment of Myocardial Perfusion in Patients Referred for Invasive Coronary Angiography Because of Suspected Coronary Artery Disease · 2022 | Their institution | $7,412 |
Professional record
- NPI
- 1962469841
- Licence
- CA C194195, LA MD15176RCalifornia C194195: Current · expires 2028-04-30
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- LA 1166383
- Taxonomy
- Cardiology (207RC0000X); Internal medicine (207R00000X)
- Mailing address
- Po Box 276950, Sacramento, CA, 95827
- NPI first listed
- 2006-04-26
- NPI last updated
- 2024-10-29
- NPI record certified
- 2024-10-29
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 4225 Lapalco Blvd, Marrero, LA, 70072 · 365 Hawthorne Ave Ste 201, Oakland, CA, 94609